Phase 2 Study of Eculizumab (Soliris) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance - Drugs.com MedNews
Links shared publicly online about this topic.
- 710total visits
Phase 2 Study of Eculizumab (Soliris) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance - Drugs.com MedNews
Eculizumab Reduced Thrombotic Microangiopathy, Restored Kidney Function and Improved Quality of Life as Reported at ASN Meeting Nov 21, 2010 - Alexion Pharmaceu
View full resource at drugs.com
Tags: Kidney Health, Urinary System, Drug, Phase 2 Clinical Trial
Most Recently Shared on November 21, 2010 at 8:02 pm By:
Phase 2 Study of Eculizumab (Soliris) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Se... http://bit.ly/9mtREG #drug
Advertisement
